INC424
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Primary Myelofibrosis (PMF)
Conditions
Primary Myelofibrosis (PMF), Post Polycythaemia Myelofibrosis (PPV MF), Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Trial Timeline
May 1, 2012 → Jan 1, 2014
NCT ID
NCT01558739About INC424
INC424 is a approved stage product being developed by Novartis for Primary Myelofibrosis (PMF). The current trial status is completed. This product is registered under clinical trial identifier NCT01558739. Target conditions include Primary Myelofibrosis (PMF), Post Polycythaemia Myelofibrosis (PPV MF), Post Essential Thrombocythaemia Myelofibrosis (PET-MF).
What happened to similar drugs?
20 of 20 similar drugs in Primary Myelofibrosis (PMF) were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03774082 | Phase 2 | Completed |
| NCT01558739 | Approved | Completed |
| NCT01493414 | Phase 3 | Completed |
Competing Products
20 competing products in Primary Myelofibrosis (PMF)